AbCellera Biologics 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- AbCellera reported Q3 2026 as a transformative quarter, led by positive top-line Phase 2 results for ABCL635, an investigational antibody for non-hormonal treatment of moderate to severe vasomotor symptoms (VMS).
- At 4 weeks after a single 600 milligram injection, ABCL635 reduced moderate and severe hot flashes by a mean of 8.8 events per day versus 3.5 events per day with placebo, a placebo-adjusted difference of 5.3 events; reductions from baseline were 83% and 33%, respectively.
- At 4 weeks, mean VMS severity decreased by 1.4 points with ABCL635 and 0.3 points with placebo, a placebo-adjusted difference of 1.1 points; 37% of ABCL635 participants had complete resolution of moderate or severe events versus 2.2% of placebo participants.
- Management said ABCL635’s placebo-adjusted 50% reduction in event frequency was approximately twice the 20 to 25% reductions reported in Phase 3 studies of besalinatant and elinzanatant, while its severity benefit was roughly 3.5- to 5-fold greater; management cautioned that cross-trial comparisons have limitations.
- ABCL635 showed a favorable tolerability profile, with no serious or severe adverse events in its treatment group and no evidence of gastrointestinal toxicity; headache was more frequent and fatigue was also reported more often, with fatigue events all mild.
- ABCL575 Phase 1 results in 40 healthy volunteers showed comparable overall adverse event rates between treatment and placebo groups, no serious or severe adverse events in the ABCL575 group, and a mean half-life of approximately 65 days. At clinically relevant dose levels, exposures remained above the 4 micrograms per milliliter efficacy target for over 12 weeks.
- AbCellera will not pursue ABCL575 in atopic dermatitis or clinical development beyond Phase 1 at this time, following discontinuations of development in the OX40/OX40 ligand class.
- The company added ABCL992, a next-generation half-life extended analog of ABCL635, to IND-enabling activities in Q3, and announced ABCL385 for an undisclosed oncology indication and ABCL646, a potential first-in-class antibody antagonist against an undisclosed ion channel target. ABCL688 and ABCL386 continued through IND-enabling activities.
- Q3 revenue was over $10 million, compared with approximately $9 million in the same quarter of 2025, mostly consisting of research fees. Research and development expenses were approximately $44 million, approximately $12 million lower than in the same quarter last year; sales, general, and administration expenses were approximately $14 million versus $25 million.
- AbCellera reported a net loss of roughly $41 million for the 3rd quarter of 2026, compared with a loss of about $57 million a year earlier, and a loss of $0.13 per share on a basic and diluted basis.
- The company completed a significantly oversubscribed $200 million capital raise. It ended the quarter with over $790 million in cash and marketable securities, including about $600 million invested in short-term marketable securities, and reported over $890 million in available liquidity including unused secured government funding.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good afternoon, and welcome to AbCellera's Q3 2026 business update conference call. My name is Kara, and I will facilitate the audio portion of today's interactive broadcast. After today's prepared remarks, we will host a question-and-answer session. If you would like to ask a question, please press star one to raise your hand. To withdraw your question, press star one again. At this time, I would like to turn the call over to Tryn Stimart, Chief Legal and Compliance Officer. You may proceed. Hello, everyone.
Thank you for joining us for AbCellera's third quarter 2026 earnings call. I'm Tryn Stimart, AbCellera's Chief Legal and Compliance Officer. Speaking on today's call are Dr. Carl Hansen, AbCellera's President and CEO, Dr. Sarah Noonberg, AbCellera's Chief Medical Officer, and Andrew Booth, AbCellera's Chief Financial Officer. During this call, we may make statements about our strategic priorities and financial outlook based on our current expectations and in accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Our statements are subject to a number of risks, uncertainties, and other factors that could cause actual results to differ materially from those described. Please review the risk factor section of our most recent Form 10-K and subsequent 10-Q filings with the SEC for a more detailed discussion of these risks.
AbCellera assumes no obligation to update any forward-looking statements to reflect events or circumstances after today's date. Our presentation today, our earnings press release, and our SEC filings are available on our investor relations website. The information we provide about our pipeline is intended for the investment community and is not promotional. As we transition to our prepared remarks, please note that this call is being recorded and will be available for replay on our investor relations website, and that all dollars referred to during the call are U.S. dollars. After our prepared remarks, we will open the line for questions and answers. I will now turn the call over to Carl.
Hey, thanks, Tryn, and thank you, everybody, for joining us today. Q3 was a transformative quarter for AbCellera, driven primarily by our positive top-line phase II results for ABCL635, which is an investigational antibody for the non-hormonal treatment of moderate to severe vasomotor symptoms, or hot flashes. The phase II study was designed to evaluate efficacy and safety at four weeks following a single 600 milligram injection of ABCL635. The data, which we announced on August 10th, show that ABCL635 has strong potential to redefine the standard of care for non-hormonal treatment of hot flashes. On the strength of these data, we have an exciting opportunity to develop a potential category-defining women's health product with clear differentiation across efficacy, safety, and convenience.
In line with this, we believe our data also significantly expands the commercial prospects for ABCL635, and we are fully committed to bringing it into late-stage development next year. In the next few slides, I will review the key results and put them into context with respect to existing therapies. Our first key efficacy endpoint was reduction in the frequency of moderate and severe hot flashes. This slide shows the effect of ABCL635 plotted as change from baseline values using both the primary analysis on the left, which included only values from weeks two, three, and four, as well as a pre-specified sensitivity analysis on the right that included week one data as well. I first note that our data shows rapid onset of benefit, with a significant placebo-adjusted treatment difference of 2.6 events already present at week one, and then increasing improvements over the full four-week period.
At four weeks, the ABCL635 group had a mean reduction of 8.8 events per day compared to a mean reduction of only 3.5 events per day in the placebo group, representing a placebo-adjusted treatment difference of 5.3 events. Expressed as a percent change from baseline, the ABCL635 group experienced an 83% reduction from baseline in daily events compared to a 33% reduction in the placebo group for a placebo-adjusted treatment difference of 50%. Notably, the benefit of ABCL635 was highly consistent across subgroup analyses, and the data were robust to a variety of sensitivity analyses. Our second key efficacy endpoint was reduction in the severity of VMS, which is reported on a three-point scale representing mild, moderate, and severe events. As with frequency, we see a rapid onset of benefit, with significant improvement at the one-week time point and increasing improvement out to four weeks.
At four weeks, the mean severity scores decreased by 1.4 points in the ABCL635 group versus 0.3 points for the placebo group, for a placebo-adjusted difference of 1.1 points. When expressed as a percent change from baseline, the ABCL635 group experienced a 58% mean reduction in severity from baseline compared to a 12% mean reduction in the placebo group, for a placebo-adjusted difference of 46%. As an alternative to reporting population averages, another valuable way to look at the data is to assess the fraction of patients that experienced different ranges of treatment benefit. In the table on the left, you can see that 37% of ABCL635 participants had complete or 100% resolution of moderate or severe events at four weeks. This compared to only 2.2% of placebo patients.
To our knowledge, these levels of complete resolution of moderate and severe events have not been reported for any non-hormonal VMS treatments and are at least comparable, if not superior, to reports from studies of hormone therapy. Furthermore, nearly 61% of ABCL635 participants had at least a 90% improvement from baseline in the number of moderate to severe events, compared to only 8.7% of placebo patients, and a full 78%, more than three-quarters of patients, had over 75% reduction. These large and clinically meaningful benefits were also observed for severity, as shown in the table on the right. While acknowledging the potential limitations in making cross-trial comparisons, it is worth evaluating our observed treatment effects against data collected similarly at four weeks from the registrational studies of the two approved small molecule NK3R antagonists, fezolinetant and elinzanetant.
Looking at placebo-adjusted reduction in frequency of moderate and severe VMS, expressed as a percentage of the baseline levels, our placebo-adjusted treatment effect is 50%, which is approximately twice as large as the 20%-25% reductions reported in phase III studies of fezolinetant and elinzanetant. An even greater difference in treatment effect was observed in improvements in VMS severity, with a roughly 3.5-5-fold greater benefit as compared to the registrational studies of fezolinetant and elinzanetant. Importantly, these markedly enhanced treatment effects were achieved without any clear signal of gastrointestinal or liver toxicity. This slide summarizes adverse events reported in at least two patients in either treatment group, regardless of relationship, occurring during the first four weeks of treatment. ABCL635 demonstrated a favorable tolerability profile across the dataset.
Overall, there was a numerically higher number of patients with at least one adverse event in the ABCL635 group compared with the placebo group. There were no serious or severe adverse events in the ABCL635 group compared to one placebo patient with a serious adverse event and two placebo patients with severe adverse events. Similar to the data in the phase I study, ABCL635 was associated with an increased incidence of headache, with the majority rated as mild and transient across both treatment groups. Fatigue was also reported more often in the ABCL635 group, although all events were mild. Importantly, we did not see any evidence of gastrointestinal toxicity in this study, despite it being consistently reported with the two approved small molecule NK3R inhibitors.
In fact, we observed a lower incidence of nausea in the ABCL635 group and no events of diarrhea or abdominal pain compared to multiple patients reporting these events in the placebo group. Summing up, our phase II data showed a combination of breakthrough efficacy and favorable tolerability. Based on this, we believe ABCL635 has the potential to redefine the standard of care for non-hormonal treatment of hot flashes. Looking forward, we are committed to advancing ABCL635 into late-stage development and are actively working through the FDA's Model-Informed Drug Development, or MIDD, program to gain alignment on dose selection for subsequent studies. We expect to disclose additional data through 12 weeks and the open-label extension, or OLE, data in early 2027.
As a reminder, in terms of efficacy, the primary objective of the phase II trial was to evaluate the benefit of a single dose of ABCL635 over the course of four weeks. This is the data we have just reviewed. The remaining portion of the 12-week data is to monitor the decline in efficacy over the final eight-week washout period, with this data used to support exposure-response modeling for late-stage dose selection. Following the initial 12-week period, OLE data will provide an additional four-week assessment, allowing us to characterize repeat dose dynamics in the treatment group alongside initial active exposure in the placebo group.
We expect to initiate late-stage development for menopause VMS in 2027. In parallel, we are expanding the indications for ABCL635 to include hot flashes caused by hormone suppression associated with breast and prostate cancer treatment, and we expect to initiate clinical trials in these two populations in 2027. Finally, today we are pleased to announce a new program, ABCL992, which is the next-generation half-life extended analog of ABCL635. ABCL992 entered IND-enabling activities in Q3. Building on our landmark data from ABCL635, we believe this program will advance another therapeutic option that provides even greater convenience to patients through extending dosing interval and facilitates broader patient reach. Moving on from ABCL635, and as previously guided, today we are presenting phase I results from our second clinical candidate, ABCL575, which is a long-acting investigational antibody targeting OX40 ligand.
ABCL575 entered clinical development as a potential best-in-class follower of Sanofi's amlitelimab, which at the time was in phase III studies for atopic dermatitis. Earlier this year, based on disappointing clinical data, development of amlitelimab was discontinued in atopic dermatitis. Separately, late-stage clinical studies of Amgen's rocatinlimab, an OX40-targeted antibody, also led to discontinuation. Based on these external results, we will not pursue development of ABCL575 in atopic dermatitis. While we believe the OX40/OX40 ligand class has potential in other autoimmune conditions, we do not currently have plans to develop it beyond phase I. With that, I'll hand it over to Sarah to discuss our top-line results from the phase I study.
Sarah? Thank you, Carl. Despite setbacks in the OX40/OX40 ligand class, the top-line results from the phase I clinical trial of ABCL575 demonstrated a favorable tolerability and PK profile that were very much in line with our target product profile.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
14 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
